For example, daratumumab in combination with CD47 blockade was effective in T-ALL cell depletion in vivo in xenograft NSG mouse models (12), which was most likely caused by myeloid effector cells since these severely immunocompromised mice do not have T or NK cells and lack a functional complement system. This evidence concerns the gene CD47 and acute lymphoblastic leukemia.